While we’re busy working on some big projects this summer, we’re re-releasing some of our most ambitious and useful reporting to date.

Last year, we set out on a mission: Collect all the best advice about what to do when your prescription drugs cost more than you can afford.

Our listeners wrote to us about their experiences getting around this most demoralizing — and distinctly American — problem in order to get the medicine they need.

Those responses allowed us to map a whole landscape of potential fixes — none a guaranteed solution for everyone, every time — but all worth knowing about.

In this episode, you’ll meet some of the intrepid navigators charting the path — including a dad on a mission to afford his daughter’s epilepsy medication, a Medicare coach who helps seniors save tens of thousands of dollars on meds, a pharmaceutical sales rep with a brilliant short-term fix, and other generous and smart fellow travelers.

We documented all their advice and more in our Prescription Drug Playbook.

Here’s a transcript of this episode.

Want weekly updates from the Arm and a Leg team, including more practical advice for dealing with the outrageous cost of health care? Sign up for our newsletter, First Aid Kit.

Send your stories and questions! Or call 724 ARM-N-LEG.

Of course we’d love for you to support this show.

See omnystudio.com/listener for privacy information.

One place you might assume is safe from prying ears is your therapy session.

But as more therapists struggle to negotiate with insurers, they’re turning to tech middlemen like BetterHelp and Headway that promise to take care of the insurance admin and match them with patients.

And these companies are sometimes recording and transcribing your sessions — and then turning around and sharing that data with social media companies and investors. And there are concerns that these confidential discussions could be used to train the next generation of chatbot therapists.

So this week, we’re bringing you an episode from our pals at Organized Money, a show about corporate consolidation and monopolies, where they speak with Linda Michaels, a psychologist and co-founder of the Psychotherapy Action Network, about the tech companies sneaking into your therapy sessions and how we got here.

And they share some good news: How one state, Illinois, passed a law in 2025 that could be a national model for encouraging more therapists to stay in-network, and ultimately, reduce reliance on these platforms.

For more on mental health coverage: Check out our episode about Abigail Burman, an attorney and expert on mental health “ghost networks” — lists of providers that turn out to be filled with inaccuracies, making it difficult for patients to get in-network care. Plus we have a whole guide from Burman on “ghostbusting” — AKA, getting your insurance to cover your mental health care. That’s in our First Aid Kit newsletter.

Here’s a transcript of this episode. We’ll be back with more Arm and a Leg in a few weeks.

Send your stories and questions. Or call 724 ARM-N-LEG.

Of course we’d love for you to support this show.

See omnystudio.com/listener for privacy information.

It’s a case you’ve (probably) never heard of: This week, the Supreme Court is hearing oral arguments in Hikma v. Amarin — a legal battle that could impact how much you ultimately pay for prescription drugs.

Here’s why the case matters: As soon as a generic version of a brand-name drug comes to market, its price typically drops by half. Within 10 years, by more than 75%. Meaning: the sooner we have access to generics, the less we pay at the pharmacy counter.

But one of the fastest legal pathways for generic companies to get their drugs to market may be about to get a lot narrower – depending on how the court rules later this year.

Amarin, a brand-name drugmaker, has accused Hikma, a generic company, of encouraging doctors to infringe on their patent for a drug called Vascepa.

The case revolves around the legal concept of skinny labels: a carveout in drug patent law that allows generic companies to bring drugs to market when one of the brand-name drug’s patents has expired, but others haven’t.

And it raises the (unexpected) question of whether it’s OK for a generic drug company to call their product the generic version of something.

Legal experts help us unpack the nerdy details – including how this case came to be, and what’s at stake for both generic drug companies and anyone looking forward to one day paying less for an expensive brand-name drug.

Want to learn how these drug monopolies work – and came to be in the first place? Check out our previous episode: Why drugs cost so much, 101: Medicine monopolies

Here's a copy of this episode's transcript.

Send your stories and questions. Or call 724 ARM-N-LEG.

And of course we’d love for you to support this show.

See omnystudio.com/listener for privacy information.